ERBB2 and breast cancer: Sabbaghi et al. reported that in HER2+ breast cancer cell lines sensitive to T-DM1, treatment with that ADC caused an increase in cyclin B1 and arrest in the G2/M phase of the cell cycle, a process that triggers the mitotic catastrophe phenotype characteristic of T-DM1 treatment.